M. Kaye Edward's most recent trade in Avidity Biosciences Inc was a trade of 22,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 27, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avidity Biosciences Inc | Edward M. Kaye | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2026 | 22,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Edward M. Kaye | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2026 | 22,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Edward M. Kaye | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2026 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Edward M. Kaye | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2026 | 13,489 | 0 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Edward M. Kaye | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2026 | 11,323 | 0 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Edward M. Kaye | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2026 | 10,034 | 0 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Edward M. Kaye | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2026 | 9,534 | 0 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Edward M. Kaye | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2026 | 6,692 | 0 | - | - | Common Stock | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 63.44 per share. | 15 Jan 2026 | 197 | 10,174 (0%) | 0% | 63.4 | 12,498 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 32.52 per share. | 08 Dec 2025 | 8,274 | 50,455 (0%) | 0% | 32.5 | 269,070 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 31.44 per share. | 08 Dec 2025 | 3,825 | 58,729 (0%) | 0% | 31.4 | 120,253 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 33.10 per share. | 08 Dec 2025 | 1,331 | 49,124 (0%) | 0% | 33.1 | 44,062 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2025 | 26,250 | 0 | - | - | Performance Stock Units | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2025 | 26,250 | 77,555 (0%) | 0% | 0 | Common Stock | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 31.33 per share. | 03 Dec 2025 | 6,367 | 64,735 (0%) | 0% | 31.3 | 199,481 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 30.76 per share. | 03 Dec 2025 | 5,222 | 72,333 (0%) | 0% | 30.8 | 160,647 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 31.15 per share. | 03 Dec 2025 | 1,681 | 63,054 (0%) | 0% | 31.1 | 52,358 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 31.32 per share. | 03 Dec 2025 | 1,231 | 71,102 (0%) | 0% | 31.3 | 38,550 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 31.85 per share. | 03 Dec 2025 | 500 | 62,554 (0%) | 0% | 31.8 | 15,923 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 66.72 per share. | 01 Dec 2025 | 28,064 | 9,977 (0%) | 0% | 66.7 | 1,872,430 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2025 | 20,000 | 0 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.25 per share. | 01 Dec 2025 | 20,000 | 38,041 (0%) | 0% | 14.3 | 285,000 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2025 | 8,064 | 0 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.40 per share. | 01 Dec 2025 | 8,064 | 18,041 (0%) | 0% | 12.4 | 99,994 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2025 | 4,317 | 0 | - | - | Restricted Stock Units | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2025 | 4,317 | 53,441 (0%) | 0% | 0 | Common Stock | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 29.56 per share. | 01 Dec 2025 | 661 | 52,780 (0%) | 0% | 29.6 | 19,540 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 30.85 per share. | 01 Dec 2025 | 651 | 51,305 (0%) | 0% | 30.8 | 20,082 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 30.34 per share. | 01 Dec 2025 | 419 | 51,956 (0%) | 0% | 30.3 | 12,712 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 30.14 per share. | 01 Dec 2025 | 405 | 52,375 (0%) | 0% | 30.1 | 12,207 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2025 | 5,175 | 0 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 65.08 per share. | 11 Nov 2025 | 5,175 | 9,977 (0%) | 0% | 65.1 | 336,789 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.66 per share. | 11 Nov 2025 | 5,175 | 15,152 (0%) | 0% | 9.7 | 49,991 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 62.80 per share. | 15 Oct 2025 | 199 | 9,977 (0%) | 0% | 62.8 | 12,497 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2025 | 25,000 | 542,801 | - | - | Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 08 Oct 2025 | 25,000 | 49,124 (0%) | 0% | 30 | 750,000 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 08 Oct 2025 | 25,000 | 74,124 (0%) | 0% | 0.6 | 15,000 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 06 Oct 2025 | 6,757 | 9,778 (0%) | 0% | 60 | 405,420 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 25.09 per share. | 03 Oct 2025 | 42,461 | 49,124 (0%) | 0% | 25.1 | 1,065,206 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 55.08 per share. | 30 Sep 2025 | 6,695 | 16,535 (0%) | 0% | 55.1 | 368,761 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 Sep 2025 | 178,500 | 37,500 | - | - | Employee Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 Sep 2025 | 144,000 | 0 | - | - | Restricted Stock Units | |
| Cytokinetics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 02 Sep 2025 | 6,756 | 23,230 (0%) | 0% | 50 | 337,800 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 20.13 per share. | 29 Aug 2025 | 45,996 | 91,585 (0%) | 0% | 20.1 | 925,858 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 20.14 per share. | 29 Aug 2025 | 14,860 | 137,581 (0%) | 0% | 20.1 | 299,260 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 29 Aug 2025 | 1,029 | 152,441 (0%) | 0% | 20 | 20,580 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 18.24 per share. | 18 Aug 2025 | 12,126 | 153,470 (0%) | 0% | 18.2 | 221,154 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2025 | 52,500 | 52,500 | - | - | Performance Stock Units | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2025 | 26,250 | 165,596 (0%) | 0% | 0 | Common Stock | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2025 | 26,250 | 26,250 | - | - | Performance Stock Units | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 38.01 per share. | 15 Jul 2025 | 328 | 29,986 (0%) | 0% | 38.0 | 12,467 | Common Stock |
| Avidity Biosciences Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 10,034 | 10,034 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 6,692 | 6,692 | - | 0 | Common Stock | |
| Cytokinetics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 32.10 per share. | 05 Jun 2025 | 3,636 | 29,658 (0%) | 0% | 32.1 | 116,716 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 10,880 | 10,880 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 7,333 | 33,294 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 38.56 per share. | 15 Apr 2025 | 324 | 25,961 (0%) | 0% | 38.6 | 12,493 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 216,000 | 216,000 | - | - | Employee Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 144,000 | 144,000 | - | - | Restricted Stock Units | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 8.67 per share. | 18 Mar 2025 | 10,382 | 148,253 (0%) | 0% | 8.7 | 90,012 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 8.27 per share. | 18 Mar 2025 | 8,907 | 139,346 (0%) | 0% | 8.3 | 73,661 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 35,500 | 132,385 (0%) | 0% | 0 | Common Stock | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 35,500 | 71,000 | - | - | Restricted Stock Units | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 26,250 | 158,635 (0%) | 0% | 0 | Common Stock | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 26,250 | 78,750 | - | - | Restricted Stock Units | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 48.93 per share. | 02 Jan 2025 | 255 | 25,637 (0%) | 0% | 48.9 | 12,477 | Common Stock |
| Stoke Therapeutics Inc | M. Kaye Edward | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 30 Dec 2024 | 35,000 | 96,885 (0%) | 0% | 0.6 | 21,000 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2024 | 35,000 | 567,801 | - | - | Employee Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 12.99 per share. | 09 Dec 2024 | 6,786 | 61,885 (0%) | 0% | 13.0 | 88,158 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 12.78 per share. | 06 Dec 2024 | 6,170 | 68,671 (0%) | 0% | 12.8 | 78,837 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 52,500 | 52,500 | - | - | Performance Stock Units | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 26,250 | 26,250 | - | - | Performance Stock Units | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 26,250 | 74,841 (0%) | 0% | 0 | Common Stock | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 21,591 | 4,317 | - | - | Restricted Stock Unit (RSU) | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 21,591 | 48,591 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 52.60 per share. | 01 Oct 2024 | 237 | 25,382 (0%) | 0% | 52.6 | 12,466 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 228 | 25,145 (0%) | 0% | 0 | Common Stock | |
| Avidity Biosciences Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 13,489 | 13,489 | - | - | Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 15.39 per share. | 20 May 2024 | 39,686 | 29,664 (0%) | 0% | 15.4 | 610,783 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 16.05 per share. | 20 May 2024 | 2,664 | 27,000 (0%) | 0% | 16.0 | 42,746 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 5,600 | 24,917 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 3,636 | 3,636 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 159,000 | 159,000 | - | - | Employee Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 105,000 | 105,000 | - | - | Restricted Stock Units | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 35,500 | 80,500 (0%) | 0% | 0 | Common Stock | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 35,500 | 106,500 | - | - | Restricted Stock Units | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 6.10 per share. | 15 Mar 2024 | 11,150 | 69,350 (0%) | 0% | 6.1 | 67,999 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 84.12 per share. | 02 Jan 2024 | 148 | 19,317 (0%) | 0% | 84.1 | 12,450 | Common Stock |
| Stoke Therapeutics Inc | Kaye M. Edward | Director, CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 200,800 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Kaye M. Edward | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 25,908 | 25,908 | - | - | Restricted Stock Unit (RSU) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 33.36 per share. | 03 Jul 2023 | 374 | 18,721 (0%) | 0% | 33.4 | 12,477 | Common Stock |
| Avidity Biosciences Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 10,000 | 10,000 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 5,000 | 18,347 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 37.71 per share. | 03 Apr 2023 | 298 | 13,347 (0%) | 0% | 37.7 | 11,238 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 213,000 | 213,000 | - | - | Employee Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 142,000 | 142,000 | - | - | Restricted Stock Unit (RSU) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 44.35 per share. | 03 Jan 2023 | 253 | 13,049 (0%) | 0% | 44.4 | 11,221 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 51.11 per share. | 03 Oct 2022 | 220 | 12,796 (0%) | 0% | 51.1 | 11,244 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 05 Aug 2022 | 11,428 | 12,576 (0%) | 0% | 50 | 571,400 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.75 per share. | 05 Aug 2022 | 11,428 | 24,004 (0%) | 0% | 8.8 | 99,995 | Common Stock |